Cite
HARVARD Citation
Tariot, P. et al. (2018). The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort. Alzheimer's & dementia. 4 (1), pp. 150-160. [Online].